![]() |
|
|
Vol. 15, Issue 8, 3673-3687, August 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Laboratory Medicine and Pathobiology, and Medicine, University of Toronto, The Banting and Best Diabetes Centre, Toronto General Hospital, Toronto, Canada M5G 2C4
Submitted November 18, 2003;
Revised May 11, 2004;
Accepted May 18, 2004
Monitoring Editor: Jennifer Lippincott-Schwartz
The intestinotrophic and cytoprotective actions of glucagon-like peptide-2 (GLP-2) are mediated by the GLP-2 receptor (GLP-2R), a member of the class II glucagon-secretin G protein-coupled receptor superfamily. Although native GLP-2 exhibits a short circulating half-life, long-acting degradation-resistant GLP-2 analogues are being evaluated for therapeutic use in human subjects. Accordingly, we examined the mechanisms regulating signaling, internalization, and trafficking of the GLP-2R to identify determinants of receptor activation and desensitization. Heterologous cells expressing the transfected rat or human GLP-2R exhibited a rapid, dose-dependent, and prolonged desensitization of the GLP-2stimulated cAMP response and a sustained GLP-2induced decrease in levels of cell surface receptor. Surprisingly, inhibitors of clathrin-dependent endocytosis failed to significantly decrease GLP-2R internalization, whereas cholesterol sequestration inhibited ligand-induced receptor internalization and potentiated homologous desensitization. The hGLP-2R localized to both Triton X-100soluble and insoluble (lipid raft) cellular fractions and colocalized transiently with the lipid raft marker caveolin-1. Although GLP-2R endocytosis was dependent on lipid raft integrity, the receptor transiently associated with green fluorescent protein tagged-early endosome antigen 1positive vesicles and inhibitors of endosomal acidification attenuated the reappearance of the GLP-2R on the cell surface. Our data demonstrate that GLP-2R desensitization and raft-dependent trafficking represent distinct and independent cellular mechanisms and provide new evidence implicating the importance of a clathrin- and dynamin-independent, lipid raft-dependent pathway for homologous G protein-coupled receptor internalization.
* Corresponding author. E-mail address: d.drucker{at}utoronto.ca.
This article has been cited by other articles:
![]() |
A. Amato, S. Baldassano, R. Serio, and F. Mule Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release Am J Physiol Gastrointest Liver Physiol, March 1, 2009; 296(3): G678 - G684. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Langlois, K. N. Cowan, Q. Shao, B. J. Cowan, and D. W. Laird Caveolin-1 and -2 Interact with Connexin43 and Regulate Gap Junctional Intercellular Communication in Keratinocytes Mol. Biol. Cell, March 1, 2008; 19(3): 912 - 928. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Dube and P. L. Brubaker Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E460 - E465. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Nelson, J. W. Sharp, M. S. Brownfield, H. E. Raybould, and D. M. Ney Localization and Activation of Glucagon-Like Peptide-2 Receptors on Vagal Afferents in the Rat Endocrinology, May 1, 2007; 148(5): 1954 - 1962. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Syme, L. Zhang, and A. Bisello Caveolin-1 Regulates Cellular Trafficking and Function of the Glucagon-Like Peptide 1 Receptor Mol. Endocrinol., December 1, 2006; 20(12): 3400 - 3411. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ueda, N. F. Neel, E. Schutyser, D. Raman, and A. Richmond Deletion of the COOH-Terminal Domain of CXC Chemokine Receptor 4 Leads to the Down-regulation of Cell-to-Cell Contact, Enhanced Motility and Proliferation in Breast Carcinoma Cells Cancer Res., June 1, 2006; 66(11): 5665 - 5675. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Estall, J. A. Koehler, B. Yusta, and D. J. Drucker The Glucagon-like Peptide-2 Receptor C Terminus Modulates {beta}-Arrestin-2 Association but Is Dispensable for Ligand-induced Desensitization, Endocytosis, and G-protein-dependent Effector Activation J. Biol. Chem., June 10, 2005; 280(23): 22124 - 22134. [Abstract] [Full Text] [PDF] |
||||